Literature DB >> 20949621

Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.

Lothar Gremer1, Torsten Merbitz-Zahradnik, Radovan Dvorsky, Ion C Cirstea, Christian Peter Kratz, Martin Zenker, Alfred Wittinghofer, Mohammad Reza Ahmadian.   

Abstract

The KRAS gene is the most common locus for somatic gain-of-function mutations in human cancer. Germline KRAS mutations were shown recently to be associated with developmental disorders, including Noonan syndrome (NS), cardio-facio-cutaneous syndrome (CFCS), and Costello syndrome (CS). The molecular basis of this broad phenotypic variability has in part remained elusive so far. Here, we comprehensively analyzed the biochemical and structural features of ten germline KRAS mutations using physical and cellular biochemistry. According to their distinct biochemical and structural alterations, the mutants can be grouped into five distinct classes, four of which markedly differ from RAS oncoproteins. Investigated functional alterations comprise the enhancement of intrinsic and guanine nucleotide exchange factor (GEF) catalyzed nucleotide exchange, which is alternatively accompanied by an impaired GTPase-activating protein (GAP) stimulated GTP hydrolysis, an overall loss of functional properties, and a deficiency in effector interaction. In conclusion, our data underscore the important role of RAS in the pathogenesis of the group of related disorders including NS, CFCS, and CS, and provide clues to the high phenotypic variability of patients with germline KRAS mutations.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20949621      PMCID: PMC3117284          DOI: 10.1002/humu.21377

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  86 in total

1.  Fluorescence methods in the study of small GTP-binding proteins.

Authors:  Mohammad Reza Ahmadian; Alfred Wittinghofer; Christian Herrmann
Journal:  Methods Mol Biol       Date:  2002

2.  Organic solvents order the dynamic switch II in Ras crystals.

Authors:  Greg Buhrman; Vesna de Serrano; Carla Mattos
Journal:  Structure       Date:  2003-07       Impact factor: 5.006

Review 3.  The ras family of oncogenes.

Authors:  C J Der
Journal:  Cancer Treat Res       Date:  1989

4.  The role of the metal ion in the p21ras catalysed GTP-hydrolysis: Mn2+ versus Mg2+.

Authors:  T Schweins; K Scheffzek; R Assheuer; A Wittinghofer
Journal:  J Mol Biol       Date:  1997-03-07       Impact factor: 5.469

5.  The response of T4 lysozyme to large-to-small substitutions within the core and its relation to the hydrophobic effect.

Authors:  J Xu; W A Baase; E Baldwin; B W Matthews
Journal:  Protein Sci       Date:  1998-01       Impact factor: 6.725

6.  Probing the structure and mechanism of Ras protein with an expanded genetic code.

Authors:  H H Chung; D R Benson; P G Schultz
Journal:  Science       Date:  1993-02-05       Impact factor: 47.728

7.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

8.  Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.

Authors:  Lothar Gremer; Bernd Gilsbach; Mohammad Reza Ahmadian; Alfred Wittinghofer
Journal:  Biol Chem       Date:  2008-09       Impact factor: 3.915

9.  The structural basis for the transition from Ras-GTP to Ras-GDP.

Authors:  Brian E Hall; Dafna Bar-Sagi; Nicolas Nassar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-04       Impact factor: 11.205

10.  Expression of p21 proteins in Escherichia coli and stereochemistry of the nucleotide-binding site.

Authors:  J Tucker; G Sczakiel; J Feuerstein; J John; R S Goody; A Wittinghofer
Journal:  EMBO J       Date:  1986-06       Impact factor: 11.598

View more
  59 in total

1.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

2.  C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.

Authors:  Michael Klüppel; Payman Samavarchi-Tehrani; Kela Liu; Jeffrey L Wrana; Aleksander Hinek
Journal:  Eur J Hum Genet       Date:  2012-02-08       Impact factor: 4.246

3.  Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination.

Authors:  Rachael Baker; Emily M Wilkerson; Kazutaka Sumita; Daniel G Isom; Atsuo T Sasaki; Henrik G Dohlman; Sharon L Campbell
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

Review 4.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

5.  Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1).

Authors:  Zhenhao Fang; Christopher B Marshall; Jiani C Yin; Mohammad T Mazhab-Jafari; Geneviève M C Gasmi-Seabrook; Matthew J Smith; Tadateru Nishikawa; Yang Xu; Benjamin G Neel; Mitsuhiko Ikura
Journal:  J Biol Chem       Date:  2016-05-18       Impact factor: 5.157

Review 6.  New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.

Authors:  Keesha E Erickson; Oleksii S Rukhlenko; Richard G Posner; William S Hlavacek; Boris N Kholodenko
Journal:  Semin Cancer Biol       Date:  2018-03-05       Impact factor: 15.707

7.  Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.

Authors:  Mohammad T Mazhab-Jafari; Christopher B Marshall; Matthew J Smith; Geneviève M C Gasmi-Seabrook; Peter B Stathopulos; Fuyuhiko Inagaki; Lewis E Kay; Benjamin G Neel; Mitsuhiko Ikura
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

8.  The Function of Embryonic Stem Cell-expressed RAS (E-RAS), a Unique RAS Family Member, Correlates with Its Additional Motifs and Its Structural Properties.

Authors:  Saeideh Nakhaei-Rad; Hossein Nakhaeizadeh; Claus Kordes; Ion C Cirstea; Malte Schmick; Radovan Dvorsky; Philippe I H Bastiaens; Dieter Häussinger; Mohammad Reza Ahmadian
Journal:  J Biol Chem       Date:  2015-05-04       Impact factor: 5.157

9.  Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes.

Authors:  Simone Martinelli; Oliver H F Krumbach; Francesca Pantaleoni; Simona Coppola; Ehsan Amin; Luca Pannone; Kazem Nouri; Luciapia Farina; Radovan Dvorsky; Francesca Lepri; Marcel Buchholzer; Raphael Konopatzki; Laurence Walsh; Katelyn Payne; Mary Ella Pierpont; Samantha Schrier Vergano; Katherine G Langley; Douglas Larsen; Kelly D Farwell; Sha Tang; Cameron Mroske; Ivan Gallotta; Elia Di Schiavi; Matteo Della Monica; Licia Lugli; Cesare Rossi; Marco Seri; Guido Cocchi; Lindsay Henderson; Berivan Baskin; Mariëlle Alders; Roberto Mendoza-Londono; Lucie Dupuis; Deborah A Nickerson; Jessica X Chong; Naomi Meeks; Kathleen Brown; Tahnee Causey; Megan T Cho; Stephanie Demuth; Maria Cristina Digilio; Bruce D Gelb; Michael J Bamshad; Martin Zenker; Mohammad Reza Ahmadian; Raoul C Hennekam; Marco Tartaglia; Ghayda M Mirzaa
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

10.  An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.

Authors:  Karen W Gripp; Katia Sol-Church; Patroula Smpokou; Gail E Graham; David A Stevenson; Heather Hanson; David H Viskochil; Laura C Baker; Bridget Russo; Nick Gardner; Deborah L Stabley; Verena Kolbe; Georg Rosenberger
Journal:  Am J Med Genet A       Date:  2015-04-25       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.